Aerovate Therapeutics (NASDAQ:AVTE – Get Free Report) and Anthem (NASDAQ:ANTX – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, analyst recommendations, profitability and earnings.
Volatility & Risk
Aerovate Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Anthem has a beta of -0.98, indicating that its share price is 198% less volatile than the S&P 500.
Profitability
This table compares Aerovate Therapeutics and Anthem’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aerovate Therapeutics | N/A | -90.19% | -77.47% |
| Anthem | N/A | -52.35% | -47.25% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aerovate Therapeutics | N/A | N/A | -$75.52 million | ($1.70) | -8.98 |
| Anthem | N/A | N/A | -$35.17 million | ($1.10) | -4.06 |
Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
90.5% of Anthem shares are held by institutional investors. 24.9% of Aerovate Therapeutics shares are held by company insiders. Comparatively, 24.5% of Anthem shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of current recommendations for Aerovate Therapeutics and Anthem, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aerovate Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
| Anthem | 1 | 0 | 1 | 0 | 2.00 |
Anthem has a consensus target price of $9.00, suggesting a potential upside of 101.52%. Given Anthem’s stronger consensus rating and higher probable upside, analysts clearly believe Anthem is more favorable than Aerovate Therapeutics.
Summary
Anthem beats Aerovate Therapeutics on 9 of the 11 factors compared between the two stocks.
About Aerovate Therapeutics
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
About Anthem
-logo-1200x675.jpg?v=20220419083428){kind=logo}
Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care guidance; and Medicare administrative services. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2017, it served 40.2 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Receive News & Ratings for Aerovate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerovate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
